Claims for Patent: 9,353,172

Summary for Patent: 9,353,172

Title:	Long acting biologically active luteinizing hormone (LH) compound
Abstract:	The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilization, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
Inventor(s):	Nordkild; Peter (Gentofte, DK), Lindenberg; Svend (Skodsborg, DK), Andersen; Claus Yding (Hellerup, DK), Andersen; Kim Vilbour (Bronshoj, DK)
Assignee:	ARTS BIOLOGICS A/S (Copenhagen, unknown)
Application Number:	14/233,455
Patent Claims:	1. A long acting biologically active luteinizing hormone (LH) compound comprising a mammal chorionic gonadotropin (CG) or a mammal LH fused to an albumin, wherein the albumin is fused to an N-terminal or a C-terminal of the mammal CG or an N-terminal or a C-terminal of the mammal LH, wherein the LH compound is selected from Product 2 consisting of SEQ ID NO: 9 and SEQ ID NO 26, Product 3 consisting of SEQ ID NO: 1 and SEQ ID NO: 28, Product 4 consisting of SEQ ID NO: 9 and SEQ ID NO: 27, Product 5 consisting of SEQ ID NO: 1 and SEQ ID NO: 29, Product 7 consisting of SEQ ID NO: 4 and SEQ ID NO: 26, Product 8 consisting of SEQ ID NO: 1 and SEQ ID NO: 30, Product 9 consisting of SEQ ID NO: 4 and SEQ ID NO: 27, or Product 10 consisting of SEQ ID NO: 1 and SEQ ID NO: 31. 2. A composition comprising the LH compound of claim 1 for subcutaneous injection. 3. A method for assisted reproductive therapy in a female mammal in need thereof comprising administering a dosage of the LH compound of claim 1 as a single bolus injection 1-4 times: (i) during the follicular phase, the dosage effective to support follicle development, or (ii) during the luteal phase for at least 2 weeks after ovulation. 4. A method for assisted reproductive therapy in a female mammal in need thereof comprising administering a dosage of the LH compound of claim 1 as a single bolus injection 1-2 times, effective to induce ovulation. 5. A method for promoting fertility of a mammalian subject in need thereof, comprising administering a dosage of the LH compound of claim 1 as a single bolus injection 1-2 times, effective to promote fertility.

Details for Patent 9,353,172

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	9,353,172	2032-07-09
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	9,353,172	2032-07-09
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	9,353,172	2032-07-09
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	9,353,172	2032-07-09
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	9,353,172	2032-07-09

International Patent Family for US Patent 9,353,172

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013010840
United States of America	2017000895
United States of America	2014228292
Russian Federation	2014103185
Mexico	2014000698